Singapore markets closed
Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,229.82 +7.14 (+0.14%) Dow
39,595.58 +82.74 (+0.21%) Nasdaq
16,386.77 +45.90 (+0.28%) Bitcoin USD
63,071.95 +1,858.36 (+3.04%) CMC Crypto 200
1,295.65 +35.44 (+2.81%)
Nuvectis Pharma, Inc. (NVCT)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 10:27AM EDT. Market open.
| Previous close | 6.40 |
| Open | 6.63 |
| Bid | 6.22 x 100 |
| Ask | 6.86 x 100 |
| Day's range | 6.40 - 6.63 |
| 52-week range | 5.92 - 18.65 |
| Volume | |
| Avg. volume | 103,896 |
| Market cap | 119.957M |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.41 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.00 |
- GuruFocus.com
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
Performance Analysis and Future Outlook Amidst Clinical Progress
GlobeNewswireNuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused
Simply Wall St.Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
© 2024 Yahoo. All rights reserved.